D.E. Shaw & Co’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.53B Buy
24,312,352
+13,063,148
+116% +$1.05B 0.92% 7
2025
Q4
$1.07B Buy
11,249,204
+2,338,849
+26% +$229M 0.59% 13
2025
Q3
$870M Buy
8,910,355
+2,155,204
+32% +$223M 0.49% 18
2025
Q2
$726M Buy
6,755,151
+2,916,007
+76% +$295M 0.51% 19
2025
Q1
$387M Buy
3,839,144
+3,075,641
+403% +$310M 0.34% 36
2024
Q4
$68.2M Sell
763,503
-992,596
-57% -$87.4M 0.05% 451
2024
Q3
$147M Buy
1,756,099
+937,465
+115% +$73.9M 0.13% 177
2024
Q2
$63M Sell
818,634
-580,159
-41% -$42.5M 0.06% 380
2024
Q1
$95.8M Buy
1,398,793
+879,341
+169% +$56.5M 0.08% 276
2023
Q4
$30M Sell
519,452
-618,105
-54% -$33M 0.03% 693
2023
Q3
$60.1M Sell
1,137,557
-28,268
-2% -$1.48M 0.06% 368
2023
Q2
$63.1M Buy
1,165,825
+694,070
+147% +$36.3M 0.06% 359
2023
Q1
$23.6M Sell
471,755
-355,371
-43% -$16.7M 0.03% 792
2022
Q4
$38.3M Sell
827,126
-994,886
-55% -$43.1M 0.04% 546
2022
Q3
$70.6M Sell
1,822,012
-854,832
-32% -$34.3M 0.08% 266
2022
Q2
$99.8M Buy
2,676,844
+2,092,621
+358% +$85.2M 0.12% 187
2022
Q1
$25.9M Sell
584,223
-872,392
-60% -$37.8M 0.02% 862
2021
Q4
$61.9M Buy
1,456,615
+1,138,662
+358% +$47.8M 0.05% 456
2021
Q3
$13.8M Buy
317,953
+217,113
+215% +$9.61M 0.01% 1274
2021
Q2
$4.31M Sell
100,840
-1,640,904
-94% -$69M ﹤0.01% 2179
2021
Q1
$67.3M Sell
1,741,744
-8,205,986
-82% -$311M 0.07% 364
2020
Q4
$358M Buy
9,947,730
+9,342,156
+1,543% +$337M 0.32% 45
2020
Q3
$23.1M Sell
605,574
-2,543,728
-81% -$98M 0.02% 753
2020
Q2
$111M Sell
3,149,302
-196,944
-6% -$7.09M 0.13% 148
2020
Q1
$109M Buy
3,346,246
+3,101,659
+1,268% +$121M 0.17% 124
2019
Q4
$11.1M Buy
244,587
+127,665
+109% +$5.34M 0.01% 1133
2019
Q3
$4.76M Sell
116,922
-305,601
-72% -$12.9M 0.01% 1686
2019
Q2
$18.2M Sell
422,523
-227,153
-35% -$8.74M 0.02% 801
2019
Q1
$24.9M Buy
649,676
+524,028
+417% +$20M 0.03% 628
2018
Q4
$4.44M Buy
125,648
+43,218
+52% +$1.57M 0.01% 1587
2018
Q3
$3.17M Sell
82,430
-822,564
-91% -$28.7M ﹤0.01% 1880
2018
Q2
$29.6M Sell
904,994
-3,492,231
-79% -$105M 0.04% 541
2018
Q1
$120M Sell
4,397,225
-1,071,968
-20% -$29.1M 0.16% 145
2017
Q4
$136M Buy
5,469,193
+4,828,654
+754% +$133M 0.19% 113
2017
Q3
$18.7M Sell
640,539
-280,076
-30% -$7.73M 0.03% 642
2017
Q2
$25.5M Sell
920,615
-88,662
-9% -$2.35M 0.04% 498
2017
Q1
$25.1M Sell
1,009,277
-1,498,460
-60% -$36.4M 0.04% 486
2016
Q4
$54.2M Buy
2,507,737
+1,801,037
+255% +$39.3M 0.09% 262
2016
Q3
$16.8M Sell
706,700
-617,951
-47% -$14.7M 0.03% 652
2016
Q2
$31M Sell
1,324,651
-947,230
-42% -$20.5M 0.06% 401
2016
Q1
$42.7M Sell
2,271,881
-639,652
-22% -$11.2M 0.08% 305
2015
Q4
$53.7M Sell
2,911,533
-2,739,965
-48% -$49.1M 0.08% 293
2015
Q3
$92.7M Buy
5,651,498
+1,323,536
+31% +$22.6M 0.14% 172
2015
Q2
$76.6M Sell
4,327,962
-1,254,364
-22% -$22.4M 0.11% 211
2015
Q1
$99.1M Sell
5,582,326
-2,370,829
-30% -$37.5M 0.15% 149
2014
Q4
$105M Buy
7,953,155
+3,072,571
+63% +$39.3M 0.14% 165
2014
Q3
$57.6M Buy
4,880,584
+1,137,962
+30% +$14.3M 0.07% 304
2014
Q2
$47.8M Buy
3,742,622
+310,174
+9% +$4.03M 0.07% 342
2014
Q1
$46.4M Sell
3,432,448
-2,470,439
-42% -$32.4M 0.07% 326
2013
Q4
$71M Sell
5,902,887
-9,505,600
-62% -$112M 0.1% 209
2013
Q3
$181M Buy
15,408,487
+4,078,945
+36% +$44.1M 0.29% 49
2013
Q2
$105M Buy
+11,329,542
New +$96.1M 0.2% 94

Other funds holding BSX

D.E. Shaw & Co's BSX Position: Q1 2026 in Review

D.E. Shaw & Co increased its Boston Scientific (BSX) stake by 116% in Q1 2026, buying an estimated $1.05B and bringing the position to 24,312,352 shares worth $1.53B. The position accounts for 0.92% of the portfolio, ranked #7.

D.E. Shaw & Co first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • D.E. Shaw & Co held 24,312,352 shares of Boston Scientific worth $1.53B as of Q1 2026.
  • D.E. Shaw & Co bought 13,063,148 Boston Scientific shares in Q1 2026, an estimated $1.05B.
  • Boston Scientific made up 0.92% of D.E. Shaw & Co's portfolio in Q1 2026, its #7 holding.
  • D.E. Shaw & Co first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.